Unity Biotechnology - UBX Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UBX shares.
View UBX analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12-month target prices for Unity Biotechnology's shares. Their UBX share price forecasts range from $5.00 to $10.00. On average, they expect the company's share price to reach $6.50 in the next year. This suggests a possible upside of 286.9% from the stock's current price.
View analysts price targets for UBX or view top-rated stocks among Wall Street analysts.

Unity Biotechnology's stock was trading at $2.74 at the start of the year. Since then, UBX shares have decreased by 38.7% and is now trading at $1.68.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our UBX earnings forecast.

Unity Biotechnology, Inc. (NASDAQ:UBX) issued its earnings results on Wednesday, November, 10th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($3.60) by $0.60.

Shares of Unity Biotechnology reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Unity Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Alyeska Investment Group L.P. (4.92%), 683 Capital Management LLC (1.69%), Mayo Clinic (1.11%), Mayo Clinic (1.11%), Renaissance Technologies LLC (0.64%) and Geode Capital Management LLC (0.64%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends.

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UBX stock can currently be purchased for approximately $1.68.

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $24.09 million and generates $240,000.00 in revenue each year. The company earns $-59,930,000.00 in net income (profit) each year or ($7.06) on an earnings per share basis.

The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.